Details
Stereochemistry | RACEMIC |
Molecular Formula | C15H23NO2 |
Molecular Weight | 249.3486 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CN(C)C[C@H]1CCCC[C@]1(O)C2=CC(O)=CC=C2
InChI
InChIKey=UWJUQVWARXYRCG-HIFRSBDPSA-N
InChI=1S/C15H23NO2/c1-16(2)11-13-6-3-4-9-15(13,18)12-7-5-8-14(17)10-12/h5,7-8,10,13,17-18H,3-4,6,9,11H2,1-2H3/t13-,15+/m1/s1
O-Desmethyl tramadol (O-Desmethyltramadol, O-DSMT) is a metabolite of tramadol. O-Desmethyltramadol is an opioid analgesic and the main active metabolite of tramadol. (+)-O-Desmethyltramadol is the most important metabolite of tramadol produced in the liver after tramadol is consumed. This metabolite is considerably more potent as a μ-opioid agonist than the parent compound. O-desmethyl tramadol, inhibits 5-hydroxytryptamine type 2C receptors expressed in xenopus oocytes. O-desmethyl tramadol inhibits functions of M(1) receptors but has little effect on those of M(3) receptors. O-desmethyl tramadol has been widely used clinically and has analgesic activity.
Approval Year
Sample Use Guides
In Vivo Use Guide
Curator's Comment: The administration of 10 mg/kg (+)-O-desmethyl tramadol in a 10-min i.v. infusion significantly altered pCO(2), pO(2), and pH values in comparison with baseline and lower-dose groups. However, 2 mg/kg administered in a 10-min i.v. infusion was enough to achieve 100% antinociception without respiratory depression in rats. https://www.ncbi.nlm.nih.gov/pubmed/10773040
Oral
Light: 15 – 30 mg
Common: 30 – 50 mg
Strong: 50 – 70+ mg
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/15976229
O-desmethyl tramadol (0.1-100 uM) inhibited acetylcholine (ACh)-induced currents in oocytes expressing the M(1) receptors (half-maximal inhibitory concentration [IC(50)] = 2 +/- 0.6 uM), whereas it did not suppress ACh-induced currents in oocytes expressing the M(3) receptor. O-desmethyl tramadol inhibited the specific binding of [(3)H]quinuclidinyl benzilate ([(3)H]QNB) to the oocytes expressed M(1) receptors (IC(50) = 10.1 +/- 0.1 uM), whereas it did not suppress the specific binding of [(3)H]QNB to the oocytes expressed M(3) receptors.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WIKIPEDIA |
Designer-drugs-O-Desmethyltramadol
Created by
admin on Sat Dec 16 02:55:53 GMT 2023 , Edited by admin on Sat Dec 16 02:55:53 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
2WA8F50C3F
Created by
admin on Sat Dec 16 02:55:53 GMT 2023 , Edited by admin on Sat Dec 16 02:55:53 GMT 2023
|
PRIMARY | |||
|
100000124493
Created by
admin on Sat Dec 16 02:55:53 GMT 2023 , Edited by admin on Sat Dec 16 02:55:53 GMT 2023
|
PRIMARY | |||
|
9838803
Created by
admin on Sat Dec 16 02:55:53 GMT 2023 , Edited by admin on Sat Dec 16 02:55:53 GMT 2023
|
PRIMARY | |||
|
C080580
Created by
admin on Sat Dec 16 02:55:53 GMT 2023 , Edited by admin on Sat Dec 16 02:55:53 GMT 2023
|
PRIMARY | |||
|
10450
Created by
admin on Sat Dec 16 02:55:53 GMT 2023 , Edited by admin on Sat Dec 16 02:55:53 GMT 2023
|
PRIMARY | |||
|
73986-53-5
Created by
admin on Sat Dec 16 02:55:53 GMT 2023 , Edited by admin on Sat Dec 16 02:55:53 GMT 2023
|
NON-SPECIFIC STEREOCHEMISTRY | |||
|
DesmetramadolOL
Created by
admin on Sat Dec 16 02:55:53 GMT 2023 , Edited by admin on Sat Dec 16 02:55:53 GMT 2023
|
PRIMARY | O-DSMT is considerably more potent as a .MU. opioid agonist compared to tramadol. Additionally, unlike tramadol, it is a high-affinity ligand of the .DELTA.- and .KAPPA.-opioid receptors.The two enantiomers of O-DSMT show quite distinct pharmacological profilesboth (+) and (-)-O-DSMT are inactive as serotonin reuptake inhibitors, but (-)-O-DSMT retains activity as a norepinephrine reuptake inhibitor, and so the mix of both the parent compound and metabolites contributes significantly to the complex pharmacological profile of tramadol. While the multiple receptor targets can be beneficial in the treatment of pain (especially complex pain syndromes such as neuropathic pain), it increases the potential for drug interactions compared to other opioids, and may also contribute to side effects. | ||
|
80456-81-1
Created by
admin on Sat Dec 16 02:55:53 GMT 2023 , Edited by admin on Sat Dec 16 02:55:53 GMT 2023
|
PRIMARY | |||
|
C166599
Created by
admin on Sat Dec 16 02:55:53 GMT 2023 , Edited by admin on Sat Dec 16 02:55:53 GMT 2023
|
PRIMARY | |||
|
DTXSID40894102
Created by
admin on Sat Dec 16 02:55:53 GMT 2023 , Edited by admin on Sat Dec 16 02:55:53 GMT 2023
|
PRIMARY | |||
|
O-DESMETHYL TRAMADOL
Created by
admin on Sat Dec 16 02:55:53 GMT 2023 , Edited by admin on Sat Dec 16 02:55:53 GMT 2023
|
PRIMARY | Originally Posted by Wikipedia: O-Desmethyltramadol (M1) is an opioid analgesic which is made in the body from tramadol. (+)-O-Desmethyltramadol is the most important metabolite of tramadol produced in the liver after tramadol is consumed. This metabolite is considerably more potent as a .MU. opioid agonist than the parent compound, and indeed is so much more potent that tramadol can to some extent be regarded as a prodrug for O-desmethyltramadol in the same way that codeine is a prodrug for morphine. Tramadol is demethylated by the liver enzyme CYP2D6 in the same way as codeine, and so similarly to the variation in effects seen with codeine, individuals who have a less active form of CYP2D6 ("poor metabolisers") will tend to get reduced analgesic effects from tramadol. The two enantiomers of O-desmethyltramadol show quite distinct pharmacological profiles: both (+) and (-)-O-desmethyltramadol are inactive as serotonin reuptake inhibitors, but (-)-O-desmethyltramadol retains activity as a noradrenaline reuptake inhibitor and so the mix of both the parent compound and metabolites produced contributes significantly to the complex pharmacological profile of tramadol. | ||
|
SUB32457
Created by
admin on Sat Dec 16 02:55:53 GMT 2023 , Edited by admin on Sat Dec 16 02:55:53 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
PRODRUG (METABOLITE ACTIVE)
SALT/SOLVATE (PARENT)